Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

E258K HCM-causing mutation in cardiac MyBP-C reduces contractile force and accelerates twitch kinetics by disrupting the cMyBP-C and myosin S2 interaction.

De Lange WJ, Grimes AC, Hegge LF, Spring AM, Brost TM, Ralphe JC.

J Gen Physiol. 2013 Sep;142(3):241-55. doi: 10.1085/jgp.201311018.

2.

Ablation of cardiac myosin-binding protein-C accelerates contractile kinetics in engineered cardiac tissue.

de Lange WJ, Grimes AC, Hegge LF, Ralphe JC.

J Gen Physiol. 2013 Jan;141(1):73-84. doi: 10.1085/jgp.201210837.

3.

A hypertrophic cardiomyopathy-associated MYBPC3 mutation common in populations of South Asian descent causes contractile dysfunction.

Kuster DW, Govindan S, Springer TI, Martin JL, Finley NL, Sadayappan S.

J Biol Chem. 2015 Feb 27;290(9):5855-67. doi: 10.1074/jbc.M114.607911. Epub 2015 Jan 12.

4.

The cMyBP-C HCM variant L348P enhances thin filament activation through an increased shift in tropomyosin position.

Mun JY, Kensler RW, Harris SP, Craig R.

J Mol Cell Cardiol. 2016 Feb;91:141-7. doi: 10.1016/j.yjmcc.2015.12.014. Epub 2015 Dec 21.

5.

Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C.

Mamidi R, Gresham KS, Li A, dos Remedios CG, Stelzer JE.

J Mol Cell Cardiol. 2015 Aug;85:262-72. doi: 10.1016/j.yjmcc.2015.06.011. Epub 2015 Jun 20.

6.

In vivo definition of cardiac myosin-binding protein C's critical interactions with myosin.

Bhuiyan MS, McLendon P, James J, Osinska H, Gulick J, Bhandary B, Lorenz JN, Robbins J.

Pflugers Arch. 2016 Oct;468(10):1685-95. doi: 10.1007/s00424-016-1873-y. Epub 2016 Aug 27.

7.

Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.

Wijnker PJ, Friedrich FW, Dutsch A, Reischmann S, Eder A, Mannhardt I, Mearini G, Eschenhagen T, van der Velden J, Carrier L.

J Mol Cell Cardiol. 2016 Aug;97:82-92. doi: 10.1016/j.yjmcc.2016.03.003. Epub 2016 Apr 22.

PMID:
27108529
8.

Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.

Stöhr A, Friedrich FW, Flenner F, Geertz B, Eder A, Schaaf S, Hirt MN, Uebeler J, Schlossarek S, Carrier L, Hansen A, Eschenhagen T.

J Mol Cell Cardiol. 2013 Oct;63:189-98. doi: 10.1016/j.yjmcc.2013.07.011. Epub 2013 Jul 26.

9.

Ablation of cardiac myosin binding protein-C disrupts the super-relaxed state of myosin in murine cardiomyocytes.

McNamara JW, Li A, Smith NJ, Lal S, Graham RM, Kooiker KB, van Dijk SJ, Remedios CG, Harris SP, Cooke R.

J Mol Cell Cardiol. 2016 May;94:65-71. doi: 10.1016/j.yjmcc.2016.03.009. Epub 2016 Mar 26.

10.

Cardiac myosin binding protein C: its role in physiology and disease.

Flashman E, Redwood C, Moolman-Smook J, Watkins H.

Circ Res. 2004 May 28;94(10):1279-89. Review.

11.

An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy.

Gajendrarao P, Krishnamoorthy N, Selvaraj S, Girolami F, Cecchi F, Olivotto I, Yacoub M.

J Cardiovasc Transl Res. 2015 Jun;8(4):232-43. doi: 10.1007/s12265-015-9624-6. Epub 2015 May 14.

PMID:
25971843
12.

COOH-terminal truncated cardiac myosin-binding protein C mutants resulting from familial hypertrophic cardiomyopathy mutations exhibit altered expression and/or incorporation in fetal rat cardiomyocytes.

Flavigny J, Souchet M, Sébillon P, Berrebi-Bertrand I, Hainque B, Mallet A, Bril A, Schwartz K, Carrier L.

J Mol Biol. 1999 Nov 26;294(2):443-56.

PMID:
10610770
13.

A gain-of-function mutation in the M-domain of cardiac myosin-binding protein-C increases binding to actin.

Bezold KL, Shaffer JF, Khosa JK, Hoye ER, Harris SP.

J Biol Chem. 2013 Jul 26;288(30):21496-505. doi: 10.1074/jbc.M113.474346. Epub 2013 Jun 19.

14.

Acceleration of crossbridge kinetics by protein kinase A phosphorylation of cardiac myosin binding protein C modulates cardiac function.

Tong CW, Stelzer JE, Greaser ML, Powers PA, Moss RL.

Circ Res. 2008 Oct 24;103(9):974-82. doi: 10.1161/CIRCRESAHA.108.177683. Epub 2008 Sep 18.

15.

The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations.

Nag S, Trivedi DV, Sarkar SS, Adhikari AS, Sunitha MS, Sutton S, Ruppel KM, Spudich JA.

Nat Struct Mol Biol. 2017 Jun;24(6):525-533. doi: 10.1038/nsmb.3408. Epub 2017 May 8.

PMID:
28481356
16.

Ablation of myosin-binding protein-C accelerates force development in mouse myocardium.

Stelzer JE, Fitzsimons DP, Moss RL.

Biophys J. 2006 Jun 1;90(11):4119-27. Epub 2006 Mar 2.

17.

Cardiac myosin binding protein C phosphorylation is cardioprotective.

Sadayappan S, Osinska H, Klevitsky R, Lorenz JN, Sargent M, Molkentin JD, Seidman CE, Seidman JG, Robbins J.

Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16918-23. Epub 2006 Oct 30.

18.

Determination of the critical residues responsible for cardiac myosin binding protein C's interactions.

Bhuiyan MS, Gulick J, Osinska H, Gupta M, Robbins J.

J Mol Cell Cardiol. 2012 Dec;53(6):838-47. doi: 10.1016/j.yjmcc.2012.08.028. Epub 2012 Sep 11.

19.

The A31P missense mutation in cardiac myosin binding protein C alters protein structure but does not cause haploinsufficiency.

van Dijk SJ, Bezold Kooiker K, Mazzalupo S, Yang Y, Kostyukova AS, Mustacich DJ, Hoye ER, Stern JA, Kittleson MD, Harris SP.

Arch Biochem Biophys. 2016 Jul 1;601:133-40. doi: 10.1016/j.abb.2016.01.006. Epub 2016 Jan 9.

PMID:
26777460
20.

Altered interactions between cardiac myosin binding protein-C and α-cardiac actin variants associated with cardiomyopathies.

Chow ML, Shaffer JF, Harris SP, Dawson JF.

Arch Biochem Biophys. 2014 May 15;550-551:28-32. doi: 10.1016/j.abb.2014.04.003. Epub 2014 Apr 13.

Supplemental Content

Support Center